Dominari Holdings Inc. (NASDAQ:DOMH - Get Free Report) saw a significant decrease in short interest in February. As of February 28th, there was short interest totalling 301,300 shares, a decrease of 68.4% from the February 13th total of 952,800 shares. Approximately 3.8% of the shares of the stock are short sold. Based on an average daily volume of 1,530,000 shares, the short-interest ratio is currently 0.2 days.
Hedge Funds Weigh In On Dominari
An institutional investor recently raised its position in Dominari stock. Renaissance Technologies LLC boosted its holdings in Dominari Holdings Inc. (NASDAQ:DOMH - Free Report) by 20.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 56,326 shares of the company's stock after buying an additional 9,400 shares during the period. Renaissance Technologies LLC owned approximately 0.89% of Dominari worth $55,000 as of its most recent SEC filing. Institutional investors and hedge funds own 42.48% of the company's stock.
Dominari Trading Up 0.2 %
Shares of DOMH stock opened at $5.58 on Thursday. Dominari has a 1 year low of $0.83 and a 1 year high of $13.58. The firm's 50 day moving average is $4.77 and its 200-day moving average is $2.76. The firm has a market capitalization of $60.89 million, a price-to-earnings ratio of -1.44 and a beta of 1.08.
Dominari Announces Dividend
The firm also recently disclosed a dividend, which was paid on Monday, March 3rd. Investors of record on Monday, February 24th were issued a $0.32 dividend. The ex-dividend date of this dividend was Monday, February 24th.
Dominari Company Profile
(
Get Free Report)
Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Dominari, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dominari wasn't on the list.
While Dominari currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
